Stay updated with breaking news from Mark Erlander. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RAS-mutated mCRC– In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulti...
Onvansertib either alone or with standard of care many benefit patients with metastatic pancreatic ductal adenocarcinoma and those with pretreated SCLC.
Cardiff Oncology, Inc. (NASDAQ: CRDF) shares are trading higher Tuesday after-hours after the company announced clinical data in pancreatic cancer and small cell lung cancer, including single-agent activity
Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical controls with ORR of 19% and mPFS of 5.0...
Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical...